AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36879301
Drug: Mentalization-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based therapy (MBT)
Trial: 36879386
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) use
Trial: 36879424
Drug: Alirocumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab with statin therapy (after achieving very low LDL-C levels)
Trial: 36879424
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with statin therapy
Trial: 36880866
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp)
Trial: 36880866
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin aspart (IAsp)
Trial: 36881032
Drug: Olamkicept 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olamkicept 600 mg
Trial: 36881032
Drug: Olamkicept 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olamkicept 300 mg
Trial: 36881034
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (2 g)
Trial: 36881446
Drug: Waitlist and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist and treatment-as-usual control
Trial: 36881458
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to controller medication (inhaled corticosteroids)
Trial: 36881542
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment for anemia and/or iron deficiency
Trial: 36881542
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment for anemia and/or iron deficiency
Trial: 36881780
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IN-alert HF state and RDI ≥ 30 episodes/h
Trial: 36882562
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline 100 mg twice daily for 12 months
Trial: 39437312
Drug: Deucravacitinib 6
RxNorm normalized name: deucravacitinib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 6 mg once daily
Trial: 36883141
Drug: Cenicriviroc (CCR2/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenicriviroc (CCR2/5 antagonist)
Trial: 36883141
Drug: Icatibant (bradykinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant (bradykinin antagonist)
Trial: 36883141
Drug: Apremilast (PDE4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (PDE4 inhibitor)
Trial: 36883141
Drug: Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alfa (inhaled DNase)
Trial: 36883141
Drug: Razuprotafib (Tie2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Razuprotafib (Tie2 agonist)
Trial: 36883238
Drug: danavorexton 112
RxNorm normalized name: Danavorexton
DrugBank: Danavorexton (DB16962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: danavorexton 112 mg
Trial: 36883362
Drug: Liraglutide (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (test drug)
Trial: 36883379
Drug: Prescription sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription sleep medications (hypnotics)
Trial: 36883379
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (therapist-led and digital)
Trial: 36883885
Drug: Doxazosin, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin, dosage and duration not specified
Trial: 36884013
Drug: D2 antagonist
RxNorm normalized name: Dopamine receptor D2 antagonist-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2 antagonist amisulpride
Trial: 36884024
Drug: Vortioxetine 5-10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 5-10 mg/day
Trial: 36884024
Drug: Vortioxetine 15-20
RxNorm normalized name: vortioxetine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 15-20 mg/day
Trial: 36884108
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous remifentanil at an initial dose of 1 μg/kg lean body weight (LBW), adjusted according to pain severity using the Dixon sequential method.
Trial: 36884114
Drug: Surgery, target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, target therapy, and TNM stage
Trial: 36884234
Drug: Methotrexate plus
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate plus prednisone (20 mg/d for 3 months and 15 mg/d for 3 months)
Trial: 36884323
Drug: Nirogacestat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirogacestat (150 mg, oral, twice daily)
Trial: 36888820
Drug: Balanced solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solution
Trial: 36889160
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5-0.75mg/kg over 40 minutes, four doses over two weeks)
Trial: 36889516
Drug: Nintedanib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib + prednisone taper
Trial: 36889516
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + prednisone taper
Trial: 36889610
Drug: MK-0616 6
RxNorm normalized name: vitamin MK 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0616 6 mg once daily
Trial: 36889610
Drug: MK-0616 12
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0616 12 mg once daily
Trial: 36889610
Drug: MK-0616 18
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0616 18 mg once daily
Trial: 36889610
Drug: MK-0616 30
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0616 30 mg once daily
Trial: 36889645
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation of vitamin B12 (1.8 μg) and folic acid (150 μg) for 6 months
Trial: 36889826
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) treatment for hyperkalaemia, followed for 6 months.
Trial: 36889827
Drug: Sleep quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep quality assessment during a 90-minute visit, evaluating determinants such as morbidity, lifestyles, psychological factors, socioeconomic variables, habitability conditions, screen time, relaxation techniques, and melatonin as a biological marker.
Trial: 36890020
Drug: Mocetinostat 70
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat 70 mg TIW plus durvalumab 1500 mg Q4W
Trial: 36890393
Drug: Mirtazapine 30
RxNorm normalized name: mirtazapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg per day for 7 days
Trial: 36890529
Drug: Arthrocentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis plus tenoxicam injection (TX group)
Trial: 36890535
Drug: Physician-administered injections
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-administered injections
Trial: 36890535
Drug: Task-shifting (nurse-administered)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Task-shifting (nurse-administered)
Trial: 36891030
Drug: Transmuscular quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmuscular quadratus lumborum block (TMQLB) with 0.4 ml/kg of 0.5% ropivacaine
Trial: 36891030
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block (PVB) with 0.4 ml/kg of 0.5% ropivacaine
Trial: 36891077
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks for 3 years
Trial: 36891649
Drug: MI-CBT (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-CBT (Motivational Interviewing and Cognitive-Behavioral Therapy)
Trial: 36891761
Drug: Postoperative anaemia
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative anaemia (lowest haemoglobin concentration < 11 g dl -1)
Trial: 36891761
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of postoperative anaemia and hypotension
Trial: 36891995
Drug: Higher muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher muscle mass assessed by creatinine excretion rate
Trial: 36892190
Drug: MW031 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MW031 (60 mg)
Trial: 36892506
Drug: UDCA-Fenofibrate group
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UDCA-Fenofibrate group (fenofibrate at a daily dose of 200 mg in addition to UDCA)
Trial: 36892506
Drug: UDCA-only group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA-only group (standard dose of UDCA)
Trial: 36892677
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin and paclitaxel administration
Trial: 36892677
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration (previously published data)
Trial: 36892676
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m²
Trial: 36892707
Drug: PAH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAH therapy escalation
Trial: 36892753
Drug: Risankizumab 360
RxNorm normalized name: RISANKIZUMAB 360 mg in 2.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 360 mg
Trial: 36892833
Drug: Regorafenib, ipilimumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib, ipilimumab, and nivolumab (RIN) at the RP2D of regorafenib dosed at 80 mg daily, ipilimumab 1 mg/kg every 6 weeks, and nivolumab 240 mg every 2 weeks.
Trial: 36892833
Drug: Regorafenib at
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib at 40 mg/d on cycle 1 and 80 mg/d on cycle 2 and beyond.
Trial: 36892847
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1)
Trial: 36892847
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg with standard-dose fulvestrant (arm 2)
Trial: 36892884
Drug: Negative Affect
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative Affect Treatment (NAT)
Trial: 36893453
Drug: TPO-RA discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPO-RA discontinuation
Trial: 36893785
Drug: nvHAP prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nvHAP prevention bundle (oral care, dysphagia screening and management, mobilisation, discontinuation of non-indicated proton-pump inhibitors, respiratory therapy)
Trial: 36893784
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral arpraziquantel 50 mg/kg (cohort 1a)
Trial: 36893784
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral praziquantel 40 mg/kg (cohort 1b)
Trial: 36893784
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral arpraziquantel 50 mg/kg (cohort 2)
Trial: 36893784
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral arpraziquantel 50 mg/kg (cohort 3)
Trial: 36893784
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral arpraziquantel 60 mg/kg (cohort 4b)
Trial: 36893935
Drug: KE+CHO (573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KE+CHO (573 mg KE/kg body mass plus 110 g glucose)
Trial: 36893935
Drug: CHO (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (110 g glucose)
Trial: 36894201
Drug: Comprehensive menstrual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive menstrual health (MH) intervention including education, support, analgesics, and menstrual products.
Trial: 36894239
Drug: Acellular carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular carbohydrate sources (e.g., flour-based whole-grain products)
Trial: 36894250
Drug: HIGH carotenoid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH carotenoid intake (13.1 mg daily)
Trial: 36894250
Drug: MED carotenoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED carotenoid intake (13.1 mg daily)
Trial: 36894250
Drug: LOW carotenoid
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW carotenoid intake (13.1 mg daily)
Trial: 36894810
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered indocyanine green (ICG)
Trial: 36894877
Drug: POC targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POC targeted coagulopathy management and intraoperative administration of 5% albumin
Trial: 36894940
Drug: Standardised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised treatment package for first-episode depression
Trial: 36895062
Drug: Non-anthracycline HER2-targeted
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anthracycline HER2-targeted treatment regimen with echocardiograms every 6 months
Trial: 36895163
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy (FT) using cryotherapy
Trial: 36896716
Drug: In-hospital observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital observation on oral diuretics (OOD)
Trial: 36896967
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment of malaria (ISTp)
Trial: 36897008
Drug: DPMAS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPMAS with sequential low-volume plasma exchange (LPE)
Trial: 36897008
Drug: Comprehensive medical
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive medical treatment (Control)
Trial: 36897140
Drug: Scheduled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intravenous ketorolac (30 mg every 6 hours)
Trial: 36897140
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 mg every 6 hours)
Trial: 36897140
Drug: Scheduled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intravenous ketorolac
Trial: 36897140
Drug: Scheduled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intravenous ketorolac and Placebo
Trial: 36897226
Drug: Tablet-based contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based contraception education intervention
Trial: 36897251
Drug: CD19 CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation therapy.
Trial: 36897251
Drug: CD19 CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and TKI as consolidation therapy.
Trial: 36897310
Drug: Endometriosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometriosis treatment
Trial: 36897310
Drug: Migraine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine treatment
Trial: 36897592
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of discount and default options
Trial: 36897592
Drug: Combination condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination condition
Trial: 36897863
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (RAT)
Trial: 38319937
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH)
Trial: 36898391
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients (booster and two doses)
Trial: 36898400
Drug: Intramuscular Ad5-nCoV
RxNorm normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Ad5-nCoV
Trial: 36898933
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor T-cell therapy
Trial: 36898949
Drug: Using Peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using Peer Support to Aid in Prevention and Treatment in Prediabetes
Trial: 36899125
Drug: MenACYW-TT booster
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACYW-TT booster vaccination with co-administration of MenB vaccine
Trial: 36899351
Drug: Structured educational
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured educational intervention involving lower limb physical exercise and daily ambulation guidelines
Trial: 36899351
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in primary care (cleansing, debridement, healing in a moist environment, multilayer compression therapy)
Trial: 36899369
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg once daily
Trial: 36899430
Drug: Silymarin 700mg
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily
Trial: 36899430
Drug: Maltodextrin 700mg
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily (Control)
Trial: 36900279
Drug: Segmental Abutting
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segmental Abutting Esophagus-Sparing (SAES) radiotherapy (45 Gy in 3 Gy daily fractions over 3 weeks)
Trial: 36900554
Drug: Ginger extract
RxNorm normalized name: ginger extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract (100 mL, 0.2 g/100 mL)
Trial: 36900554
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (200 mL)
Trial: 36900811
Drug: Continued physical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued physical activity on prescription at a healthcare center (HCC)
Trial: 36900872
Drug: SUNFRAIL questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUNFRAIL questionnaire administered by seven centers.
Trial: 36902139
Drug: BCL-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCL-2 inhibitors (specific drugs not detailed)
Trial: 36902139
Drug: PD-1/PD-L1 pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 pathway inhibitors (specific drugs not detailed)
Trial: 36902217
Drug: MRD-directed therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned